Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates

Ichiro Koyama, Tatsuo Kawai, David Andrews, Svetlan Boskovic, Ognjenka Nadazdin, Siew Lin Wee, Hiroshi Sogawa, Dong Li Wu, R. Neal Smith, Robert B. Colvin, David H. Sachs, A. Benedict Cosimi

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background. The authors previously reported thromboembolic complications associated with anti-CD154 monoclonal antibody (mAb) treatment in nonhuman primates. The underlying mechanisms of this complication and its management have not been established. Methods. Eighty cynomolgus monkey renal allograft recipients treated with anti-CD154 mAb were studied for the incidence of thrombosis and its prophylaxis. Results. Without anticoagulation prophylaxis, thromboembolic complications were seen in 5 of 11 recipients. With addition of perioperative heparin, the incidence was decreased to 2 of 10. No further improvement was observed by adding intraoperative prostaglandin (PG) E 1. However, addition of ketorolac tromethamine to PGE1 and heparin decreased the incidence of thrombosis (one of eight). Most recently, the authors have found that ketorolac administration alone resulted in no thrombosis in 25 consecutive recipients. Conclusions. Ketorolac is remarkably effective in preventing thromboembolism associated with anti-CD154 mAb treatment, suggesting the mechanism underlying this complication may be related to platelet activation leading to enhanced aggregation.

Original languageEnglish
Pages (from-to)460-462
Number of pages3
JournalTransplantation
Volume77
Issue number3
DOIs
StatePublished - Feb 15 2004

Fingerprint

Thrombophilia
Primates
Ketorolac
Thrombosis
Monoclonal Antibodies
Heparin
Incidence
Ketorolac Tromethamine
Macaca fascicularis
Alprostadil
Thromboembolism
Platelet Activation
Prostaglandins E
Allografts
Kidney

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. / Koyama, Ichiro; Kawai, Tatsuo; Andrews, David; Boskovic, Svetlan; Nadazdin, Ognjenka; Wee, Siew Lin; Sogawa, Hiroshi; Wu, Dong Li; Smith, R. Neal; Colvin, Robert B.; Sachs, David H.; Cosimi, A. Benedict.

In: Transplantation, Vol. 77, No. 3, 15.02.2004, p. 460-462.

Research output: Contribution to journalArticle

Koyama, I, Kawai, T, Andrews, D, Boskovic, S, Nadazdin, O, Wee, SL, Sogawa, H, Wu, DL, Smith, RN, Colvin, RB, Sachs, DH & Cosimi, AB 2004, 'Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates', Transplantation, vol. 77, no. 3, pp. 460-462. https://doi.org/10.1097/01.TP.0000110291.29370.C0
Koyama, Ichiro ; Kawai, Tatsuo ; Andrews, David ; Boskovic, Svetlan ; Nadazdin, Ognjenka ; Wee, Siew Lin ; Sogawa, Hiroshi ; Wu, Dong Li ; Smith, R. Neal ; Colvin, Robert B. ; Sachs, David H. ; Cosimi, A. Benedict. / Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. In: Transplantation. 2004 ; Vol. 77, No. 3. pp. 460-462.
@article{eb0418f3f8904c468d22c555d8fe0032,
title = "Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates",
abstract = "Background. The authors previously reported thromboembolic complications associated with anti-CD154 monoclonal antibody (mAb) treatment in nonhuman primates. The underlying mechanisms of this complication and its management have not been established. Methods. Eighty cynomolgus monkey renal allograft recipients treated with anti-CD154 mAb were studied for the incidence of thrombosis and its prophylaxis. Results. Without anticoagulation prophylaxis, thromboembolic complications were seen in 5 of 11 recipients. With addition of perioperative heparin, the incidence was decreased to 2 of 10. No further improvement was observed by adding intraoperative prostaglandin (PG) E 1. However, addition of ketorolac tromethamine to PGE1 and heparin decreased the incidence of thrombosis (one of eight). Most recently, the authors have found that ketorolac administration alone resulted in no thrombosis in 25 consecutive recipients. Conclusions. Ketorolac is remarkably effective in preventing thromboembolism associated with anti-CD154 mAb treatment, suggesting the mechanism underlying this complication may be related to platelet activation leading to enhanced aggregation.",
author = "Ichiro Koyama and Tatsuo Kawai and David Andrews and Svetlan Boskovic and Ognjenka Nadazdin and Wee, {Siew Lin} and Hiroshi Sogawa and Wu, {Dong Li} and Smith, {R. Neal} and Colvin, {Robert B.} and Sachs, {David H.} and Cosimi, {A. Benedict}",
year = "2004",
month = "2",
day = "15",
doi = "10.1097/01.TP.0000110291.29370.C0",
language = "English",
volume = "77",
pages = "460--462",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates

AU - Koyama, Ichiro

AU - Kawai, Tatsuo

AU - Andrews, David

AU - Boskovic, Svetlan

AU - Nadazdin, Ognjenka

AU - Wee, Siew Lin

AU - Sogawa, Hiroshi

AU - Wu, Dong Li

AU - Smith, R. Neal

AU - Colvin, Robert B.

AU - Sachs, David H.

AU - Cosimi, A. Benedict

PY - 2004/2/15

Y1 - 2004/2/15

N2 - Background. The authors previously reported thromboembolic complications associated with anti-CD154 monoclonal antibody (mAb) treatment in nonhuman primates. The underlying mechanisms of this complication and its management have not been established. Methods. Eighty cynomolgus monkey renal allograft recipients treated with anti-CD154 mAb were studied for the incidence of thrombosis and its prophylaxis. Results. Without anticoagulation prophylaxis, thromboembolic complications were seen in 5 of 11 recipients. With addition of perioperative heparin, the incidence was decreased to 2 of 10. No further improvement was observed by adding intraoperative prostaglandin (PG) E 1. However, addition of ketorolac tromethamine to PGE1 and heparin decreased the incidence of thrombosis (one of eight). Most recently, the authors have found that ketorolac administration alone resulted in no thrombosis in 25 consecutive recipients. Conclusions. Ketorolac is remarkably effective in preventing thromboembolism associated with anti-CD154 mAb treatment, suggesting the mechanism underlying this complication may be related to platelet activation leading to enhanced aggregation.

AB - Background. The authors previously reported thromboembolic complications associated with anti-CD154 monoclonal antibody (mAb) treatment in nonhuman primates. The underlying mechanisms of this complication and its management have not been established. Methods. Eighty cynomolgus monkey renal allograft recipients treated with anti-CD154 mAb were studied for the incidence of thrombosis and its prophylaxis. Results. Without anticoagulation prophylaxis, thromboembolic complications were seen in 5 of 11 recipients. With addition of perioperative heparin, the incidence was decreased to 2 of 10. No further improvement was observed by adding intraoperative prostaglandin (PG) E 1. However, addition of ketorolac tromethamine to PGE1 and heparin decreased the incidence of thrombosis (one of eight). Most recently, the authors have found that ketorolac administration alone resulted in no thrombosis in 25 consecutive recipients. Conclusions. Ketorolac is remarkably effective in preventing thromboembolism associated with anti-CD154 mAb treatment, suggesting the mechanism underlying this complication may be related to platelet activation leading to enhanced aggregation.

UR - http://www.scopus.com/inward/record.url?scp=10744220010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220010&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000110291.29370.C0

DO - 10.1097/01.TP.0000110291.29370.C0

M3 - Article

C2 - 14966427

AN - SCOPUS:10744220010

VL - 77

SP - 460

EP - 462

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -